Cited by 966Bone Metabolism and DiseasesBone health and osteoporosis researchBone and Dental Protein Studies

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

Poole, Kenneth E. S., Van Bezooijen, Rutger L., Loveridge, Nigel, Hamersma, Herman, Papapoulos, Socrates E., Löwik, Clemens W., Reeve, Jonathan·2005·The FASEB Journal

DOI 10.1096/fj.05-4221fje

Open this paper in CoChat — free account

Abstract

Osteocytes are the most abundant cells in bone and are ideally located to influence bone turnover through their syncytial relationship with surface bone cells. Osteocyte‐derived signals have remained largely enigmatic, but it was recently reported that human osteocytes secrete sclerostin, an inhibitor of bone formation. Absent sclerostin protein results in the high bone mass clinical disorder sclerosteosis. Here we report that within adult iliac bone, newly embedded osteocytes were negative for sclerostin staining but became positive at or after primary mineralization. The majority of mature osteocytes in mineralized cortical and cancellous bone was positive for sclerostin with diffuse staining along dendrites in the osteocyte canaliculi. These findings provide for the first time in vivo evidence to support the concept that osteocytes secrete sclerostin after they become embedded in a mineralized matrix to limit further bone formation by osteoblasts. Sclerostin did not appear to influence the formation of osteocytes. We propose that sclerostin production by osteocytes may regulate the linear extent of formation and the induction or maintenance of a lining cell phenotype on bone surfaces. In doing so, sclerostin may act as a key inhibitory signal governing skeletal microarchitecture.

Integrity signals

Registry

Crossref · 10.1096/fj.05-4221fje

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G., Sutherland, M. K., Geoghegan, J. C., Yu, C., Hayes, T., Skonier, J. E., Shpektor, D., Jonas, M., Kovacevich, B. R., Staehling‐Hampton, K., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,114
Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Self-citation
Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist
van Bezooijen, R. L., Roelen, B. A. J., Visser, A., van der Wee-Pals, L. J. A., de Wilt, E., Karperien, M., Hamersma, H. A., Papapoulos, S. E., ten Dijke, P., & Löwik, C. W. G. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031454 · Cited by 893
Self-citation
Loss of Osteocyte Integrity in Association with Microdamage and Bone Remodeling After Fatigue In Vivo
Verborgt, O., Gibson, G. J., & Schaffler, M. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.60 · Cited by 731
Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells
Dobnig, H., & Turner, R. T. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628403 · Cited by 614
Periosteum: biology, regulation, and response to osteoporosis therapies
Allen, M. R., Hock, J. M., & Burr, D. B. (2004) · Bone · doi:10.1016/j.bone.2004.07.014 · Cited by 449
The Death of Osteocytes via Apoptosis Accompanies Estrogen Withdrawal in Human Bone
Tomkinson, A., REEVE, J., Shaw, R. W., & Noble, B. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.9.4200 · Cited by 417
Self-citation

Show all 34 references

Research works printed but not linked: 2

Warmington K., 2004, Sclerostin antagonism in adult rodents, via monoclonal antibody mediated blockade, increases bone mineral density and implicates sclerostin as a key regulator of bone mass during adulthood (Abstract), J. Back Musculoskeletal. Rehabil., 19, S56
10.1210/jc.82.9.3128 · DOI

Sorted by citations

Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
The amazing osteocyte
Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells
Florencio-Silva, R., Sasso, G. R. D. S., Sasso-Cerri, E., Simões, M. J., & Cerri, P. S. (2015) · BioMed Research International · doi:10.1155/2015/421746 · Cited by 2,044
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin
Robling, A. G., Niziolek, P. J., Baldridge, L. A., Condon, K. W., Allen, M. R., Alam, I., Mantila, S. M., Gluhak-Heinrich, J., Bellido, T. M., Harris, S. E., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705092200 · Cited by 1,350
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Mechanisms of bone development and repair
Salhotra, A., Shah, H. N., Lévi, B., & Longaker, M. T. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00279-w · Cited by 1,302
The Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment
Schett, G., & Gravallese, E. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.153 · Cited by 947
Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength
Li, X., Ominsky, M. S., Niu, Q., Sun, N., Daugherty, B., D’Agostin, D. M., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 941
Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction.
Tatsumi, S., Ishii, K., Amizuka, N., Li, M., Kobayashi, T., Kohno, K., Ito, M., Takeshita, S., & Ikeda, K. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.001 · Cited by 848
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G. R., Stouch, B., Fang, L., & Posvar, E. L. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
New perspectives on osteogenesis imperfecta
Forlino, A., Cabral, W. A., Barnes, A. M., & Marini, J. C. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.81 · Cited by 727
Sclerostin Mediates Bone Response to Mechanical Unloading Through Antagonizing Wnt/β-Catenin Signaling
Lin, C., Jiang, X., Dai, Z., Guo, X., Weng, T., Wang, J., Li, Y., Feng, G., Gao, X., & He, L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090411 · Cited by 648
The cell biology of bone metabolism
Datta, H. K., Ng, W. F., Walker, J. A., Tuck, S. P., & Varanasi, S. S. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.048868 · Cited by 614
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate
Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S., & Oursler, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805133106 · Cited by 556
Parathyroid hormone: anabolic and catabolic actions on the skeleton
Silva, B. C. C., & Bilezikian, J. P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.005 · Cited by 564
Mechanosensation and transduction in osteocytes
Klein-Nulend, J., Bakker, A. D., Bacabac, R. G., Vatsa, A., & Weinbaum, S. (2013) · Bone · doi:10.1016/j.bone.2012.10.013 · Cited by 528
Osteocytes: master orchestrators of bone
Schaffler, M. B., Cheung, W.-Y., Majeska, R., & Kennedy, O. (2014) · Calcified Tissue International · doi:10.1007/s00223-013-9790-y · Cited by 514
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025900 · Cited by 503
Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation
Qing, H., Ardeshirpour, L., Divieti Pajevic, P., Dusevich, V., Jähn, K., Kato, S., Wysolmerski, J., & Bonewald, L. F. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1567 · Cited by 489
Molecular mechanosensors in osteocytes
Qin, L., Liu, W., Cao, H., & Xiao, G. (2020) · Bone Research · doi:10.1038/s41413-020-0099-y · Cited by 484
Networks and hubs for the transcriptional control of osteoblastogenesis
Lian, J. B., Stein, G. S., Javed, A., van Wijnen, A. J., Stein, J. L., Montecino, M. A., Hassan, M. Q., Gaur, T., Lengner, C. J., & Young, D. W. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9001-5 · Cited by 473
Role and mechanism of action of sclerostin in bone
Delgado‐Calle, J., Sato, A. Y., & Bellido, T. (2016) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 465
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis
Langdahl, B. L., Ferrari, S., & Dempster, D. W. (2016) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x16670154 · Cited by 439
Bone Quality: The Determinants of Bone Strength and Fragility
Fonseca, H., Moreira‐Gonçalves, D., Coriolano, H.-J. A., & Duarte, J. A. (2013) · Sports Medicine · doi:10.1007/s40279-013-0100-7 · Cited by 456
Osteocytes as Dynamic Multifunctional Cells
Bonewald, L. F. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.018 · Cited by 457
Osteoblast and osteocyte: Games without frontiers
Capulli, M., Paone, R., & Rucci, N. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.05.003 · Cited by 413
How Fibroblast Growth Factor 23 Works
Liu, S., & Quarles, L. D. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010068 · Cited by 415
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 409
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men
Mödder, U. I., Hoey, K. A., Amin, S., McCready, L. K., Achenbach, S. J., Riggs, B. L., Melton, L. J., & Khosla, S. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.217 · Cited by 403
Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
O’Brien, C. A., Plotkin, L. I., Galli, C., Goellner, J. J., Gortázar, A. R., Allen, M. R., Robling, A. G., Bouxsein, M., Schipani, E., Turner, C. H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002942 · Cited by 396
Osteocyte-Driven Bone Remodeling
Bellido, T. (2014) · Calcified Tissue International · doi:10.1007/s00223-013-9774-y · Cited by 384
Architecture of the osteocyte network correlates with bone material quality
Kerschnitzki, M., Kollmannsberger, P., Burghammer, M. C., Duda, G. N., Weinkamer, R., Wagermaier, W., & Fratzl, P. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1927 · Cited by 361
Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease
Hu, L., Chen, W., Qian, A., & Li, Y.-P. (2024) · Bone Research · doi:10.1038/s41413-024-00342-8 · Cited by 359
Bone morphogenetic proteins and their antagonists
Gazzerro, E., & CANALIS, E. M. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9000-6 · Cited by 337
Sclerostin: Current Knowledge and Future Perspectives
Moester, M. J. C., Papapoulos, S. E., Löwik, C. W. G. M., & van Bezooijen, R. L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9372-1 · Cited by 345
Self-citation
Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis
Appel, H., Ruiz‐Heiland, G., Listing, J., Zwerina, J., i, M. H., Müeller, R. B., Haibel, H., Baraliakos, X., Hempfing, A., Rudwaleit, M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24888 · Cited by 326
Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator Function
Leupin, O., Piters, E., Halleux, C. M., Hu, S., Krämer, I., Morvan, F., Bouwmeester, T., Schirle, M., Bueno-Lozano, M., Fuentes, F. J. R., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.190330 · Cited by 304
Osteocyte RANKL: New insights into the control of bone remodeling
Xiong, J., & O’Brien, C. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1547 · Cited by 295
Mechanosensation and transduction in osteocytes
Bonewald, L. F. (2006) · BoneKEy-Osteovision · doi:10.1138/20060233 · Cited by 283
Local communication on and within bone controls bone remodeling
Henriksen, K., Neutzsky-Wulff, A. V., Bonewald, L. F., & Karsdal, M. A. (2009) · Bone · doi:10.1016/j.bone.2009.03.671 · Cited by 292
Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP-Stimulated Bone Formation
van Bezooijen, R. L., Svensson, J. P., Eefting, D., Visser, A., van der Horst, G., Karperien, M., Quax, P. H. A., Vrieling, H., Papapoulos, S. E., ten Dijke, P., et al. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061002 · Cited by 286
Self-citation
BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway
Kamiya, N., Ye, L., Kobayashi, T., Mochida, Y., Yamauchi, M., Kronenberg, H. M., Feng, J. Q., & Mishina, Y. M. (2008) · Development · doi:10.1242/dev.025825 · Cited by 279
Wnt/β-Catenin Signaling Is a Component of Osteoblastic Bone Cell Early Responses to Load-bearing and Requires Estrogen Receptor α
Armstrong, V. J., Muzylak, M., Sunters, A., Zaman, G., Saxon, L., Price, J. S., & Lanyon, L. E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703224200 · Cited by 276
Functional Biomaterials for Bone Regeneration: A Lesson in Complex Biology
Armiento, A. R., Hatt, L. P., Rosenberg, G. S., Thompson, K., & Stoddart, M. J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909874 · Cited by 282
The impact of microgravity on bone in humans
Grimm, D. G., Grosse, J., Wehland, M., Mann, V., Reseland, J. E., Sundaresan, A., & Corydon, T. J. (2016) · Bone · doi:10.1016/j.bone.2015.12.057 · Cited by 283
Osteocyte: the unrecognized side of bone tissue
Rochefort, G. Y., Pallu, S., & Benhamou, C. L. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1194-5 · Cited by 268
The osteocyte as a signaling cell
Delgado‐Calle, J., & Bellido, T. (2021) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 280
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones
Ominsky, M. S., Li, C., Li, X., Tan, H. L. E., Lee, E., Barrero, M., Asuncion, F., Dwyer, D., Han, C.-Y. E., Vlasseros, F., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.307 · Cited by 264
Wnt and the Wnt signaling pathway in bone development and disease
Wang, Y. (2014) · Frontiers in bioscience · doi:10.2741/4214 · Cited by 255
Control of the SOST Bone Enhancer by PTH Using MEF2 Transcription Factors
Leupin, O., Krämer, I., Collette, N. M., Loots, G. G., Natt, F., Kneissel, M., & Keller, H. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070804 · Cited by 248
Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient mice
Krämer, I., Loots, G. G., Studer, A., Keller, H., & Kneissel, M. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090730 · Cited by 247
Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited
Teti, A. M., & Zallone, A. Z. (2008) · Bone · doi:10.1016/j.bone.2008.09.017 · Cited by 245
Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo
Woo, S. M., Rosser, J., Dusevich, V., Kalajzic, I., & Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.465 · Cited by 243
Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered
Moustafa, A., Sugiyama, T., Prasad, J., Zaman, G., Gross, T. S., Lanyon, L. E., & Price, J. S. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1656-4 · Cited by 243
Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice
Yao, W., Cheng, Z., Busse, C., Pham, A., Nakamura, M. C., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23454 · Cited by 241
Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism
Atkins, G. J., Rowe, P. S., Lim, H. P., Welldon, K. J., Ormsby, R. T., Wijenayaka, A. R., Zelenchuk, L. V., Evdokiou, A., & Findlay, D. M. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.345 · Cited by 249
Matrix Metalloproteinases in Bone Resorption, Remodeling, and Repair
Paiva, K. B. S., & Granjeiro, J. M. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.05.001 · Cited by 245
Involvement of WNT/β-catenin Signaling in the Treatment of Osteoporosis
Rossini, M., Gatti, D., & Adami, S. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9749-z · Cited by 239
Osteoblasts in osteoporosis: Past, emerging, and future anabolic targets
Marie, P. J., & Kassem, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0132 · Cited by 234
Characterization of the Structural Features and Interactions of Sclerostin
Veverka, V., Henry, A. J., Slocombe, P. M., Ventom, A. M., Mulloy, B., Muskett, F. W., Muzylak, M., Greenslade, K. J., Moore, A., Zhang, L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807994200 · Cited by 236
Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats
Li, X., Warmington, K. S., Niu, Q., Asuncion, F., Barrero, M., Grisanti, M. S., Dwyer, D., Stouch, B., Thway, T. M., Stolina, M., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.182 · Cited by 231
Parathyroid hormone — a bone anabolic and catabolic agent
POOLE, K., & REEVE, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.07.004 · Cited by 230
Self-citation
Osteocyte Signaling in Bone
Schaffler, M. B., & Kennedy, O. D. (2012) · Current Osteoporosis Reports · doi:10.1007/s11914-012-0105-4 · Cited by 227
Skeletal sexual dimorphism: relative contribution of sex steroids, GH–IGF1, and mechanical loading
Callewaert, F., Sinnesael, M., Gielen, E., Boonen, S., & Vanderschueren, D. (2010) · Journal of Endocrinology · doi:10.1677/joe-10-0209 · Cited by 233
Osteocyte apoptosis and control of bone resorption following ovariectomy in mice
Emerton, K. B., Hu, B., Woo, A. A., Sinofsky, A., Hernandez, C., Majeska, R. J., Jepsen, K. J., & Schaffler, M. B. (2010) · Bone · doi:10.1016/j.bone.2009.11.006 · Cited by 220
Wnt Signaling: A Key Regulator of Bone Mass
Baron, R., Rawadi, G., & Roman‐Roman, S. (2006) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)76004-5 · Cited by 221
The chronic kidney disease — Mineral bone disorder (CKD-MBD): Advances in pathophysiology
Hruska, K. A., Sugatani, T., Agapova, O. A., & Fang, Y. (2017) · Bone · doi:10.1016/j.bone.2017.01.023 · Cited by 221
Catabolic and anabolic actions of parathyroid hormone on the skeleton.
da Silva, B. C., Costa, A. G., Cusano, N. E., Kousteni, S., & Bilezikian, J. P. (2011) · PubMed · doi:10.3275/7925 · Cited by 215
Overview of treatment approaches to osteoporosis
Langdahl, B. L. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15024 · Cited by 222
Osteocytic signalling pathways as therapeutic targets for bone fragility
Plotkin, L. I., & Bellido, T. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.71 · Cited by 206
Bone remodelling: its local regulation and the emergence of bone fragility
Martin, T. J., & Seeman, E. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.006 · Cited by 211
Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response
Atkins, G. J., Welldon, K. J., Halbout, P., & Findlay, D. M. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0728-6 · Cited by 206
Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management
Black, D. M., Abrahamsen, B., Bouxsein, M., Einhorn, T. A., & Napoli, N. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00001 · Cited by 207
Wnt Signaling in Bone Development and Disease: Making Stronger Bone with WntsPreprint
Regard, J. B., Zhong, Z. A., Williams, B. O., & Yang, Y. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007997 · Cited by 202
Osteocyte regulation of bone mineral: a little give and take
Atkins, G. J., & Findlay, D. M. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1915-z · Cited by 194
Toward the biomimetic implant surface: Biopolymers on titanium-based implants for bone regeneration
Tejero, R., Anitua, E., & Orive, G. (2014) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2014.01.001 · Cited by 190
Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma
McDonald, M. M., Reagan, M. R., Youlten, S. E., Mohanty, S. T., Seckinger, A., Terry, R. L., Pettitt, J. A., Simic, M. K., Cheng, T. L., Morse, A., et al. (2017) · Blood · doi:10.1182/blood-2017-03-773341 · Cited by 186
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post‐bortezomib monotherapy
Terpos, E., Christoulas, D., Katodritou, E., Bratengeier, C., Gkotzamanidou, M. A., Michalis, E., Delimpasi, S., Pouli, A. G., Meletis, J., Kastritis, E., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27342 · Cited by 184
The complexity of chronic kidney disease–mineral and bone disorder across stages of chronic kidney disease
Graciolli, F. G., Neves, K. R., Barreto, F. C., Barreto, D. V., dos Reis, L. M., Canziani, M. E. F., Sabbagh, Y., Carvalho, A. B., Jorgetti, V., Elias¹, R. M., et al. (2017) · Kidney International · doi:10.1016/j.kint.2016.12.029 · Cited by 184
Pro-Inflammatory Cytokines TNF-Related Weak Inducer of Apoptosis (TWEAK) and TNFα Induce the Mitogen-Activated Protein Kinase (MAPK)-Dependent Expression of Sclerostin in Human Osteoblasts
Vincent, C., Findlay, D. M., Welldon, K. J., Wijenayaka, A. R., Zheng, T. S., Haynes, D. R., Fazzalari, N. L., Evdokiou, A., & Atkins, G. J. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090305 · Cited by 188
Targeting subchondral bone for treating osteoarthritis: what is the evidence?
Tat, S. K., Lajeunesse, D., Pelletier, J., & Martel‐Pelletier, J. (2010) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.08.004 · Cited by 188
Biphasic and Dosage-Dependent Regulation of Osteoclastogenesis by β-Catenin
Wei, W., Zeve, D., Suh, J. M., Wang, X., Du, Y., Zerwekh, J. E., Dechow, P. C., Graff, J. M., & Wan, Y. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05980-11 · Cited by 183
The osteocyte: A multifunctional cell within the bone
Tresguerres, F. G. F., Torres, J., López-Quiles, J., Hernández, G., Vega, J. A., & Tresguerres, I. F. (2019) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2019.151422 · Cited by 184
Wnt signaling in bone metabolism
Kubota, T., Michigami, T., & Ozono, K. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0064-8 · Cited by 187
Sirt1 Is a Regulator of Bone Mass and a Repressor of Sost Encoding for Sclerostin, a Bone Formation Inhibitor
Cohen‐Kfir, E., Artsi, H., Levin, A., Abramowitz, E., Bajayo, A., Gurt, I., Zhong, L., D’Urso, A., Toiber, D., Mostoslavsky, R., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1128 · Cited by 182
Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways
Krause, C., Korchynskyi, O., de Rooij, K. E., Weidauer, S. E., de Gorter, D. J. J., van Bezooijen, R. L., Hatsell, S. J., Economides, A. N., Mueller, T. D., Löwik, C. W. G. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.153890 · Cited by 181
Self-citation
Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
Chavassieux, P., Chapurlat, R. D., Portero-Muzy, N., Roux, J.-P., Garcia, P., Brown, J. P., Libanati, C. R., Boyce, R. W., Wang, A., & Grauer, A. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3735 · Cited by 179
Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption–formation cycles?
Sapir‐Koren, R., & Livshits, G. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2808-0 · Cited by 180
Single‐ and Multiple‐Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women
McColm, J., Hu, L.-J., Womack, T., Tang, C.-C., & Chiang, A. Y. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2092 · Cited by 173
CKD-Induced Wingless/Integration1 Inhibitors and Phosphorus Cause the CKD–Mineral and Bone Disorder
Fang, Y., Ginsberg, C., Seifert, M. E., Agapova, O. A., Sugatani, T., Register, T. C., Freedman, B. I., Monier‐Faugere, M., Malluche, H. H., & Hruska, K. A. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013080818 · Cited by 173
Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII–p38MAPK–pS249/T252RB Pathway
Yu‐Lee, L., Yu, G., Lee, Y., Lin, S.-C., Pan, J., Pan, T., Yu, K., Liu, B., Creighton, C. J., Rodriguez‐Canales, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1051 · Cited by 173
The molecular mechanism behind bone remodelling: a review
Proff, P., & Römer, P. (2009) · Clinical Oral Investigations · doi:10.1007/s00784-009-0268-2 · Cited by 183
Disuse Osteoporosis: Clinical and Mechanistic Insights
Rolvien, T., & Amling, M. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00836-1 · Cited by 178
Emerging therapeutic opportunities for skeletal restoration
Kawai, M., Mödder, U. I., Khosla, S., & Rosen, C. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3299 · Cited by 161
In vitro and in vivo approaches to study osteocyte biology
Kalajzić, I., Matthews, B. G., Torreggiani, E., Harris, M. A., Pajevic, P. D., & Harris, S. E. (2012) · Bone · doi:10.1016/j.bone.2012.09.040 · Cited by 165

Authors: Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J.
Affiliations: University of Cambridge (GB)
Department of Endocrinology and Metabolic Diseases Leiden University Medical Centre Leiden Netherlands
South Africa
Leiden University (NL)
ORCID: Poole, Kenneth E. S.
Loveridge, Nigel
Hamersma, Herman
Papapoulos, Socrates E.
Löwik, Clemens W.
Reeve, Jonathan
Venue: The FASEB Journal
Publisher: Wiley
Published: 2005-08-25
Volume: 19
Issue: 13
Pages: 1842-1844
ISSN: 0892-6638 (ISSN-L)
1530-6860
DOI: 10.1096/fj.05-4221fje
OpenAlex: W1970864109
Cited by: 965
References: 34
Citations by year: 2026: 21 · 2025: 28 · 2024: 32 · 2023: 39 · 2022: 38 · 2021: 45 · 2020: 74 · 2019: 63 · 2018: 55 · 2017: 53 · 2016: 66 · 2015: 67 · 2014: 55 · 2013: 62 · 2012: 63
FWCI: 10.29
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: The FASEB Journal (publishedVersion)
PubMed (publishedVersion)
Funders: Medical Research Council
National Osteoporosis Society
European Commission (LSHM‐CT‐2003‐503020)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
Keywords: sclerostin, osteocytes, bone formation inhibition, sclerosteosis, osteoblasts, bone mineralization, bone lining cells, bone turnover
MeSH terms: Aged, Alkaline Phosphatase, Antibodies, Monoclonal, Biopsy, Bone and Bones, Bone Development, Bone Diseases, Developmental, Bone Resorption, Cell Differentiation, Coloring Agents, Female, Genetic Markers, Humans, Image Processing, Computer-Assisted, Immunohistochemistry, Male, Microscopy, Fluorescence, Middle Aged, Models, Biological, Osteoblasts, Osteocytes, Osteogenesis, RNA, Messenger, Time Factors, Tolonium Chloride, Signal Transduction, Bone Remodeling, Bone Morphogenetic Proteins, Adaptor Proteins, Signal Transducing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks